EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A low-cost breast cancer prognosis tool using machine learning

Iván Romarico Gonzalez-Espinoza, Abraham Castro-Ponce, María Castelló-Pons, Sergio Jímenez-Monferrer, Edgar Cardona-Ferrer, Gabriela Juárez-Salazar, Diego A Juárez-Salazar, Mariana Chiquillo-Domínguez, Enrique Miguel-Cruz, Laura E González-Lozada

Breast Disease · 2024

DOI: 10.1177/15581551241289699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Disease, 2024. Verfasst von Iván Romarico Gonzalez-Espinoza und 9 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Machine learning (ML) models are cost-effective tools that can establish a prognosis by considering clinical, genomic, and histological data from breast cancer patients. In this study, we evaluate the performance of 12 ML models in predicting the overall survival of breast cancer patients from “The Cancer Genome Atlas-Breast Cancer” database at 60 months of follow-up. The models evaluated were Logistic Regression (LR), Ridge Classifier (RC), Least Absolute Shrinkage and Selection Operator (LASSO), K-Nearest Neighbors (KNN), Naive Bayes (NB), Linear Discriminant Analysis (LDA), Decision Tree (DT), Multilayer Perceptron (MP), Stochastic Gradient Descent (SGD), Support Vector Machine (SVM), Random Forest (RF), and XGBoost (XGB). The most accurate models were NB (86.76%) and SGD (85.29%). The models with the highest sensitivity were SGD (93.75%), MP (91.67%), and NB (89.89%), while the models with the highest specificity were KNN (95.0%), DT (90.0%), and LASSO (85.0%). The models with the highest area under the ROC curve were LDA (90.83%), LASSO (90.1%), and LR (89.79%). The most relevant variables were “Previous Diagnosis of Cancer,” “Presence of Tumor,” “Ancillary Therapy,” and “Histology.” Our findings demonstrate that AI tools for predicting patient outcomes are a viable option when expensive prognostic genomic tools are not available. According to our results, NB and LASSO show promising performance in predicting the prognosis of breast cancer patients. Further studies with data from developing countries are needed to improve the performance of these tools.

Zitieren

APA

Gonzalez-Espinoza, I. R., Castro-Ponce, A., Castelló-Pons, M., Jímenez-Monferrer, S., Cardona-Ferrer, E., Juárez-Salazar, G., Juárez-Salazar, D. A., Chiquillo-Domínguez, M., Miguel-Cruz, E., & González-Lozada, L. E. (2024). A low-cost breast cancer prognosis tool using machine learning. Breast Disease. https://doi.org/10.1177/15581551241289699

Vancouver

Gonzalez-Espinoza IR, Castro-Ponce A, Castelló-Pons M, Jímenez-Monferrer S, Cardona-Ferrer E, Juárez-Salazar G, et al. A low-cost breast cancer prognosis tool using machine learning. Breast Disease. 2024. doi:10.1177/15581551241289699

BibTeX
@article{GonzalezEspinoza2024,
  author = {Gonzalez-Espinoza, Iván Romarico and Castro-Ponce, Abraham and Castelló-Pons, María and Jímenez-Monferrer, Sergio and Cardona-Ferrer, Edgar and Juárez-Salazar, Gabriela and Juárez-Salazar, Diego A and Chiquillo-Domínguez, Mariana and Miguel-Cruz, Enrique and González-Lozada, Laura E},
  title = {A low-cost breast cancer prognosis tool using machine learning},
  journal = {Breast Disease},
  year = {2024},
  doi = {10.1177/15581551241289699}
}
Kostenlos starten →